Alnylam Pharmaceuticals Stock Revenue
| ALNY Stock | USD 244.89 1.91 0.77% |
Alnylam Pharmaceuticals fundamentals help investors to digest information that contributes to Alnylam Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Alnylam Stock. The fundamental analysis module provides a way to measure Alnylam Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Alnylam Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 1.8 B | 1.9 B |
Alnylam | Revenue |
Alnylam Pharmaceuticals Company Revenue Analysis
Alnylam Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Alnylam Pharmaceuticals Revenue | 1.83 B |
Most of Alnylam Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alnylam Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Alnylam
Projected quarterly revenue analysis of Alnylam Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Alnylam Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Alnylam Pharmaceuticals' stock price.
Alnylam Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Alnylam Pharmaceuticals is extremely important. It helps to project a fair market value of Alnylam Stock properly, considering its historical fundamentals such as Revenue. Since Alnylam Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Alnylam Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Alnylam Pharmaceuticals' interrelated accounts and indicators.
| 0.11 | -0.25 | -0.32 | 0.12 | 0.32 | ||
| 0.11 | 0.03 | -0.24 | 1.0 | 0.25 | ||
| -0.25 | 0.03 | -0.26 | 0.02 | 0.27 | ||
| -0.32 | -0.24 | -0.26 | -0.26 | -1.0 | ||
| 0.12 | 1.0 | 0.02 | -0.26 | 0.27 | ||
| 0.32 | 0.25 | 0.27 | -1.0 | 0.27 |
Click cells to compare fundamentals
Alnylam Revenue Historical Pattern
Today, most investors in Alnylam Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Alnylam Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Alnylam Pharmaceuticals revenue as a starting point in their analysis.
Alnylam Pharmaceuticals Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Alnylam Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Alnylam Pharmaceuticals reported 1.83 B of revenue. This is 76.03% lower than that of the Biotechnology sector and 146.1% higher than that of the Health Care industry. The revenue for all United States stocks is 80.62% higher than that of the company.
Alnylam Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alnylam Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics of similar companies.Alnylam Pharmaceuticals is currently under evaluation in revenue category among its peers.
Alnylam Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Alnylam Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Alnylam Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Alnylam Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Alnylam Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alnylam Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alnylam Pharmaceuticals' value.| Shares | T. Rowe Price Investment Management,inc. | 2024-09-30 | 3.1 M | Norges Bank | 2024-06-30 | 2.3 M | Geode Capital Management, Llc | 2024-09-30 | 2.1 M | Jpmorgan Chase & Co | 2024-06-30 | 1.8 M | American Century Companies Inc | 2024-09-30 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.5 M | Orbis Allan Gray Ltd | 2024-09-30 | 1.3 M | Legal & General Group Plc | 2024-06-30 | 926.3 K | Bellevue Group Ag | 2024-09-30 | 809.1 K | Capital World Investors | 2024-09-30 | 16.5 M | Fmr Inc | 2024-09-30 | 14.7 M |
Alnylam Fundamentals
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0292 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 30.11 B | ||||
| Shares Outstanding | 128.98 M | ||||
| Shares Owned By Insiders | 0.42 % | ||||
| Shares Owned By Institutions | 98.05 % | ||||
| Number Of Shares Shorted | 3.7 M | ||||
| Price To Earning | (22.92) X | ||||
| Price To Book | 976.27 X | ||||
| Price To Sales | 15.08 X | ||||
| Revenue | 1.83 B | ||||
| Gross Profit | 868.6 M | ||||
| EBITDA | (258.24 M) | ||||
| Net Income | (440.24 M) | ||||
| Cash And Equivalents | 2.27 B | ||||
| Cash Per Share | 18.41 X | ||||
| Total Debt | 2.68 B | ||||
| Debt To Equity | 5.63 % | ||||
| Current Ratio | 3.48 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | 104.16 M | ||||
| Short Ratio | 4.60 X | ||||
| Earnings Per Share | (2.62) X | ||||
| Price To Earnings To Growth | (0.49) X | ||||
| Target Price | 301.21 | ||||
| Number Of Employees | 2.1 K | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 31.59 B | ||||
| Total Asset | 3.83 B | ||||
| Retained Earnings | (7.01 B) | ||||
| Working Capital | 2.01 B | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 62.1 M | ||||
| Net Asset | 3.83 B |
About Alnylam Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alnylam Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.